Hudson Bay Capital Management
BEAM icon

Hudson Bay Capital Management’s Beam Therapeutics BEAM Stock Holding History

Hudson Bay Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$416K – 1407
2025
Q4 		$416K Sell
15,000
-55,000
-79% -$1.4M ﹤0.01% 892
2025
Q3 		$1.7M Buy
70,000
+25,000
+56% +$497K 0.01% 781
2025
Q2 		$765K Buy
+45,000
New +$784K ﹤0.01% 1003
2025
Q1 		– Sell
-100,000
Closed -$2.48M – 1309
2024
Q4 		$2.48M Sell
100,000
-15,000
-13% -$383K 0.01% 624
2024
Q3 		$2.82M Buy
115,000
+77,500
+207% +$2M 0.01% 521
2024
Q2 		$879K Buy
+37,500
New +$921K ﹤0.01% 614

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Hudson Bay Capital Management's BEAM Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 15,000 shares — an estimated $416K sold.

Hudson Bay Capital Management first reported a position in BEAM in Q2 2024 and held it in 6 quarters. The position peaked at $2.82M in Q3 2024. 253 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 15,000 Beam Therapeutics shares in Q1 2026, an estimated $416K.
  • Hudson Bay Capital Management first reported a position in Beam Therapeutics in Q2 2024 and held it in 6 quarters.
  • Hudson Bay Capital Management's Beam Therapeutics position peaked at $2.82M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.